Update on LATIFY Phase III trial of ceralasertib

The LATIFY Phase III trial evaluating ceralasertib in combination with Imfinzi for advanced non-small cell lung cancer did not meet its primary endpoint of overall survival. The trial focused on patients whose disease progressed after prior immunotherapy and chemotherapy without actionable genomic alterations. While the results were disappointing, AstraZeneca remains committed to developing new treatments for lung cancer. The combination therapy was generally well-tolerated, with a safety profile consistent with the individual drugs. Data from the trial will be presented at an upcoming medical meeting. AstraZeneca continues its research in oncology, aiming to redefine cancer care and improve patient outcomes through innovative therapies and combinations.